Fighting to cure disease, one fragment at a time
Your Subtitle text
| zenobia Therapeutics is focused on delivering optimized, efficient therapeutics for diseases with limited patient populations through fragment-based lead discovery | ||
Newly incorporated, Zenobia Therapeutics is dedicated to curing diseases through collaborations with outstanding scientists and organizations, as well as with our own internal drug discovery programs. We use state-of-the-art technologies and continually optimize our methods to ensure rapid identification and optimization of fragment hits into small molecule inhibitors. Although our technology is independent of therapeutic area, we have chosen to focus on neurological and muscular degenerative diseases for our internal programs. Collaborations need not be disease specific. Zenobia's management has over 25 years of experience in drug discovery, fragment-based lead discovery, X-ray crystallography and structure-based drug design. Our team has produced lead compounds for a number of programs and we have determined several hundred novel and co-crystal structures. The backbone of Zenobia's scientific team is the protein biochemistry and crystallization group. In their combined careers, this group has cloned, expressed and crystallized over 100 human drug targets including many that were not found in any public database. Facile access to crystals and crystal structures allows Zenobia Therapeutics to rapidly execute a fragment-based lead discovery program. Our computational, medicinal chemistry and drug discovery experts use this structural information as a map to generate multiple lead compounds for each drug discovery program. This gives Zenobia and our partners a higher probability of success in rapidly identifying high-quality clinical candidates. |
07/29/08 |